Everest Medicines Limited

1952

KYG3224E1061

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 13:41:44 08/07/2025 HKT			5-day change	1st Jan Change
67.15 ^HKD	+0.07%		+5.25%	+38.64%

07-04	Everest Medicines Limited - Special Call
06-13	Everest Medicines' Controlling Shareholder to Offload 25 Million Shares	MT

Everest Medicines Says Exec Director & CEO Not Disposed Of Any Shares

Published on 13/06/2025 at 09:36

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Everest Medicines Limited

Everest Medicines Limited - Special Call	07-04
Everest Medicines' Controlling Shareholder to Offload 25 Million Shares	06-13	MT
Everest Medicines Says Exec Director & CEO Not Disposed Of Any Shares	06-13	RE
Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor Ever001 at the 62nd Congress of the European Renal Association	06-09	CI
Everest Medicines Gets China Nod for Kidney Damage Drug	05-07	MT
Everest Medicines Says NMPA Granted Full Approval For Nefecon	05-07	RE
Everest Medicines Limited Announces Full Approval by National Medical Products Administration	05-07	CI
Everest Medicines to Drop B Marker from Stock Short Name	04-25	MT
Everest Medicines' 2024 Loss Widens; Shares Slide 6%	03-26	MT
Everest Medicines Limited, 2024 Earnings Call, Mar 26, 2025	03-26
Everest Medicines Posts FY Net Income RMB -1,041.4 Million	03-26	RE
Everest Medicines Limited Reports Earnings Results for the Full Year Ended December 31, 2024	03-26	CI
Hong Kong Stocks Break Rise on Lower Import Data, Trade War Concerns; Everest Medicines Surges on Cancer Vaccine First Dose	03-07	MT
Everest Medicines Shares Surge 18% as First Patient Dosed in Cancer Drug Trial	03-07	MT
Everest Medicines Limited - Special Call	03-06
Everest Medicines Presents Complete Maintenance Period Data for Etrasimod at ECCO 2025	02-26	CI
Everest Medicines Limited Announces Change of Address of Principal Place of Business in Hong Kong	01-10	CI
Everest Medicines Clarifies Unusual Price, Trading Volume Movements	01-09	MT
Everest Medicines Announces First Prescription of VELSIPITY in Greater Bay Area, Officially Benefiting Mainland China Patients	12-18	CI
Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY by the National Medical Products Administration of China for the Treatment of Moderately to Severely Active Ulcerative Colitis	12-17	CI
Everest Medicines Announces the First Prescription of VELSIPITY® Issued in Macau, Officially Beginning to Benefit Asian Patients	12-12	CI
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Ever001	12-04	CI
Everest Medicines Limited - Special Call	12-04
Everest Medicines Announces Acceptance of Velsipity New Drug Application in Hong Kong	12-02	CI
Everest Medicines Announces Nefecon, the World's First Approved Treatment for IGA Nephropathy, Is Included in China's National Reimbursement Drug List	11-28	CI

Chart Everest Medicines Limited

Duration

Period

1952: Dynamic Chart

Everest Medicines Ltd is a biopharmaceutical company primarily engaged in the discovering, developing, manufacturing and commercializing transformative pharmaceutical products and vaccines. The Company has built a product pipeline across renal, anti-infective, and autoimmune diseases. The Companyâs products portfolio includes Nefecon (TARPEYO) using in the renal therapeutic area, XERAVA (eravacycline) using in the treatment of infections caused by susceptible gram-positive, gram-negative and anaerobic pathogens including those multidrug resistant isolates and other products. The Company conducts its business in the domestic and overseas markets.

Employees

665

Sector

Pharmaceuticals

Calendar

09-02 - Q2 2025 Earnings Release (Projected)

More about the company